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Purpose: To investigate the characteristics of papillary thyroid carcinoma (PTC) with cystic changes 
visible on ultrasonography (US). 
Methods: This study included 553 PTCs in 553 patients between January 2003 and August 
2004. One radiologist with 10 years of experience in thyroid imaging retrospectively reviewed the 
preoperative US images. Two different groups were formed according to two different reference points 
(group 1, 25%; group 2, 50%) of the cystic component. Patients between the groups were compared 
according to their clinicopathologic characteristics. Disease-free survival (DFS) was estimated. Cox’s 
multivariate proportional hazards regression model was used to identify the effect of variable factors 
on the recurrence risk.
Results: Fifty-six patients (10.1%) were confirmed to have tumor recurrence within the follow-up 
period. Thirty-five patients had regional metastasis, one had distant metastasis, eight had multiple 
site metastases, and 12 had biochemical recurrence. PTC patients with a ≤ 50% or PTC patients with 
a ≤ 25% cystic component did not have a statistically significant longer DFS than those with a >50% 
(hazard ratio [HR], 1.118; 95% confidence interval [CI], 0.255 to 4.910; P=0.883) or those with 
a >25% cystic component (HR, 0.569; 95% CI, 0.164 to 1.976; P=0.375), respectively. Moreover, 
independent predictors of recurrence were pathologic size, male gender, and lymph node metastasis, 
not a >50% or >25% cystic component. 
Conclusion: The proportion of the cystic component in PTCs did not affect DFS.
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Introduction
Thyroid cancers usually appear solid, but those with predominant cystic changes (>50% of the 
nodule) can be observed in 2.5%-6% of all thyroid cancers [1,2]. Cystic papillary thyroid cancer 
(PTC) commonly shows the presence of tridimensional fragments, anisonucleosis, nuclear bars, 
pseudoinclusions, powdery chromatin, cytoplasmic vacuoles, metaplastic cytoplasm, and autolysis 
on cytologic specimens [3]. The accuracy of fine-needle aspiration (FNA) in the diagnosis of thyroid 
cancer on ultrasonography (US) was lower for thyroid cancers with cystic changes than for those 
without the changes, owing to a difficulty in obtaining adequate cells, interpretation errors of smears 
due to scant cellularity, and degenerative changes in the specimens [4-8].Ja Young Kim, et al.
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Cystic PTC may differ from a cystic change of papillary carcinoma 
on US. Cystic PTC can manifest as either cystic or solid masses on 
US [9]. This imaging-pathologic discordance-a mass appearing solid 
on US, but diagnosed as cystic PTC on pathology-is due to cystic 
changes within the mass that are too small to be detected on US 
[9]. Although we often come across PTCs with a cystic appearance 
on US, there have been no studies on the outcome of PTC showing 
cystic contents. In this study, we investigated the characteristics of 
PTC with cystic changes visible on US, comparing them to those 
showing a solid appearance on US. 
Materials and Methods
Study Population
This retrospective study was approved by the Institutional Review 
Board of a Severance Hospital and required neither patient approval 
nor informed consent for the review of patients’ images and medical 
records. Between January 2003 and August 2004, a total of 923 
consecutive patients underwent surgery for thyroid cancer at our 
institution. Among them, 888 patients were pathologically confirmed 
as having conventional PTC. Patients were excluded from this study 
for the following reasons: (1) no available preoperative US images 
(n=176), (2) coexisting cancer at another primary site that could 
affect the prognosis (n=39), (3) previous history of thyroid surgery 
due to thyroid cancer or recurrent lesions (n=98), (4) no available 
or insufficient pathology reports (n=11), or (5) follow-up loss after 
surgery without any available clinical records (n=11). The largest 
lesion was selected in patients with multiple PTC to avoid data 
clustering. Finally, this study included 553 thyroid nodules in 553 
patients. Seventy of them were men (12.7%; mean age, 45.6 years; 
range, 22 to 74 years) and 483 were women (87.3%; mean age, 
45.9 years; range, 17 to 79 years). The mean age of the 553 patients 
was 45.9 years (range, 17 to 79 years). Detailed characteristics of 
the patients of this study are presented in Table 1.
The clinical records and pathologic reports were reviewed by 
two radiologists. Patients were followed up for a mean period 
of 87.3 months. All included patients underwent total/near-total 
thyroidectomy with bilateral central neck lymph node dissection 
(CCND) or subtotal thyroidectomy/hemithyroidectomy with unilateral 
CCND. Sixty-four patients also underwent lateral neck lymph node 
dissection for metastatic lymph nodes. Two hundred ninety-two 
patients underwent subsequent radioactive iodine ablation after 
thyroidectomy for adjuvant therapy.
Pathology reports were reviewed on the basis of the findings of 
the nodule size, extrathyroidal extension, multiplicity, lymph node 
metastases, and underlying thyroid disease. Extrathyroidal extension 
was categorized into perithyroidal soft-tissue extension, skeletal 
muscle invasion, or massive extension into the trachea, larynx, 
esophagus, and recurrent laryngeal nerve. Metastatic lymph nodes 
were categorized according to location as central and lateral neck 
lymph nodes. Multiplicity of the thyroid included both multifocality 
(one lobe) and bilaterality (both lobes) of PTCs.
Ultrasonographic Analysis
All patients underwent preoperative US examinations. One 
radiologist (JYK) with 10 years of experience in thyroid imaging 
retrospectively reviewed the preoperative US images. HDI 3000 
or 5000 scanners (Phillips, Bothell, WA, USA) using a bandwidth 
of a 7- to 12-MHz transducer was used in patients who had US 
examinations performed at our institution. Twenty-five patients 
had US examinations done in outside hospitals. These patients 
were included in this study because the US images obtained were 
available and determined to be of good quality. The composition of 
the cancer on US was divided into two categories (less than a 25% 
or 50% cystic component) according to the percentage of cystic 
components within the cancer lesions. 
Postoperative Follow-up
Follow-up clinical examinations were performed every 6 months 
during the first 3 years after surgery, and annually thereafter. Blood 
Table 1. Detailed demographics of the 553 patients included
Variable No. (%)
Age (yr)
     Mean±SD 45.9±12.4
     Median (interquartile range) 45 (37-54)
Gender (female:male) 483:70
Surgery
     Total or near-total 374 (67.6)
     Subtotal 65 (11.8)
     Hemithyroidectomy 114 (20.6)
Pathologic size (mm)
     Mean±SD 12±9.3
     Median (interquartile range) 10 (5-15)
Extrathyroidal extension 
     No 321 (58)
     Yes 232 (42)
Central lymph node metastasis  241 (43.6)
Lateral lymph node metastasis  64 (11.6)
Underlying Hashimoto thyroiditis  89 (16.1)
Multiplicity  145 (26.2)
Radioactive iodine ablation 292 (52.8)
Recurrence 56 (10.1)Papillary thyroid carcinoma with cystic changes
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analysis of serum thyroid stimulating hormone (TSH), free thyroxine, 
thyroglobulin (Tg), and anti-Tg antibody were included in the routine 
follow-up examination every 12 months. TSH-suppressed serum 
Tg measurement was routinely used in the follow-up of patients 
with thyroid cancer. In some patients, stimulated Tg values were 
used on the basis of a physician’s decision. Neck US examinations 
were also performed routinely. 
18F-Fluorodeoxyglucose positron 
emission tomography with computed tomography, 
131I-iodine whole 
body scan (WBS), or neck computed tomography examinations 
were performed, selectively. The follow-up interval of patients was 
clinically defined and calculated as the time from the initial thyroid 
operation to the most recent clinical evaluation.
Cancer recurrence was evaluated by reviewing all available 
examinations for each patient. Recurrence was conclusively 
confirmed by (1) cytopathology obtained from US-FNA and 
surgical excision, (2) elevated serum Tg, and (3) abnormal uptake 
Table 2. Clinicopathologic characteristics of the 553 patients between the two different groups 
Characteristic
50% Cystic component 25% Cystic component
≤50% (n=546) >50% (n=7) P-value ≤25% (n=530) >25% (n=23) P-value
Age (yr) 0.825 0.883
     Mean±SD 45.9±12.4 44.9±10.8 45.9±12.3 46.3±14.5
     Median (interquartile range) 45 (37-54) 46 (37-56) 45 (37-54) 43 (35-58)
Gender  0.047 0.058
     Female 479 (87.7) 4 (57.1) 466 (87.9) 17 (73.9)
     Male 67 (12.3) 3 (42.9) 64 (12.1) 6 (26.1)
Surgery  0.479 0.321
     Total or near-total 368 (67.4) 6 (85.7) 355 (67) 19 (82.6)
     Subtotal 64 (11.7) 1 (14.3) 63 (11.9) 2 (8.7)
     Hemithyroidectomy 114 (20.9) 0 (0) 112 (21.1) 2 (8.7)
Pathologic size (mm) <0.001 <0.001
     Mean±SD 11.8±8.9 29.4±19.5 11.5±8.6 23.7±15.3
     Median (interquartile range) 10 (5-15) 30 (11-40) 9 (5-15) 25 (7-35)
Extrathyroidal extension  0.137 0.060
     No 319 (58.4) 2 (28.6) 312 (58.9) 9 (39.1)
     Yes 227 (41.6) 5 (71.4) 218 (41.1) 14 (60.9)
Central lymph node metastasis 0.476 0.675
     No 309 (56.6) 3 (42.9) 300 (56.6) 12 (52.2)
     Yes 237 (43.4) 4 (57.1) 230 (43.4) 11 (47.8)
Lateral lymph node metastasis 0.189 0.039
     No 484 (88.6) 5 (71.4) 472 (89.1) 17 (73.9)
     Yes 62 (11.4) 2 (28.6) 58 (10.9) 6 (26.1)
Underlying echogenicity  0.605 0.559
     No 457 (83.7) 7 (100) 443 (83.6) 21 (91.3)
     Yes 89 (16.3) 0 (0) 87 (16.4) 2 (8.7)
Multiplicity 0.682 0.988
     No 402 (73.6) 6 (85.7) 391 (73.8) 17 (73.9)
     Yes  144 (26.4) 1 (14.3) 139 (26.2) 6 (26.1) 
Radioactive iodine ablation 0.712 0.951
     No 257 (47.1) 4 (57.1) 250 (47.2) 11 (47.8)
     Yes 289 (52.9) 3 (42.9) 280 (52.8) 12 (52.2)
Recurrence 0.152 0.720
     No 492 (90.1) 5 (71.4) 477 (90) 20 (87)
     Yes 54 (9.9) 2 (28.6) 53 (10) 3 (13)Ja Young Kim, et al.
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on radioactive iodine WBS, which suggests regional or distant 
metastases. Patients with undetectable serum Tg, with no regional 
recurrence on the neck US, with benign cytology results, and with no 
regional or distant metastasis on WBS or other imaging studies were 
considered to be disease free.
Statistical Analysis
Two different groups were formed using two different reference 
points of the cystic component, respectively. The two reference 
points were defined as a 25% and 50% cystic component because 
the percentage of cystic component of the thyroid nodules was 
visually categorized. Group 1 was divided by the reference point of a 
50% cystic component. Group 2 was divided by the reference point 
of a 25% cystic component. All statistical analyses were carried out 
for both groups.
The chi-squared test or Fisher exact test was used to compare 
categorical variables. We compared continuous variables between 
the groups by using the independent 2-sample t-test. Disease-free 
survival (DFS) was defined as the time from the date of surgery to 
the date of death or the date of the last follow-up. Multivariate 
Cox proportional hazards regression models were used to identify 
whether a cystic component of more than 50% or 25% could be 
an independent predictor of recurrence during the follow-up period, 
after adjusting the known prognostic factors (tumor size, gender, 
age, extrathyroidal extension, and lymph node metastasis). To check 
the proportional hazards assumption, logs (-log[survival probability]) 
for different categories were plotted against time to ensure that the 
curves were reasonably parallel. All probability assumptions were 
appropriate. A P-value of less than 0.05 was considered statistically 
significant. Statistical analyses were performed with SAS ver. 9.1.3 
(SAS Institute Inc., Cary, NC, USA).
Results
Table 2 summarizes the clinicopathologic features of the two 
groups. Fifty-six patients (10.1%) were confirmed to have tumor 
recurrence within the follow-up period (Table 3). Recurrence in 
patients was diagnosed on the basis of cytopathologic results (n=40), 
imaging features (n=5) showing uptake in the neck area on WBS 
(n=4), highly suspicious features of metastasis on cross-sectional 
imaging (n=1), or biochemical recurrence showing elevated serum 
Tg levels (n=12). Thirty-five patients had regional metastasis, one 
had distant metastasis, eight had multiple site metastases, and 12 
had biochemical recurrence.
In group 1, thyroid cancers with a >50% cystic component were 
significantly larger than those with a ≤50% cystic component in the 
case of the mean pathologic size (P<0.001). There was a significant 
difference in gender (P=0.047). The follow-up period ranged 
from 34 to 115 months (mean, 76.3±29.1 months) for the 7 PTC 
patients with a >50% cystic component and from 5 to 119 months 
(mean, 85.7±27.3 months) for the 546 patients with a ≤50% cystic 
component. Two recurrences occurred during the follow-up period 
in PTC patients with a >50% cystic component (28.6%), whereas 
54 recurrences occurred in patients with ≤50% cystic component 
(9.9%) (P=0.152). The cystic component of a tumor was not an 
independent predictor of recurrence (hazard ratio [HR], 1.118; 95% 
confidence interval [CI], 0.255 to 4.910; P=0.883), according to 
the multiple Cox proportional hazards model (Table 4). Independent 
predictors of recurrence were pathologic size (HR, 1.035; 95% CI, 
1.008 to 1.064; P=0.012), male gender (HR, 2.185; 95% CI, 1.093 
to 4.369; P=0.027), and lymph node metastasis (HR, 2.213; 95% 
Table 3. Demographic and clinicopathologic characteristics of 
56 patients with recurrence
Characteristic No. (%)
Age (yr)
     Mean (range) 45.6 (24-79)
     Median (interquartile range) 45.5 (31.3-55)
Gender (female:male) 39:17
Surgery
     Total or near-total 47 (83.9)
     Subtotal 3 (5.4)
     Hemithyroidectomy 6 (10.7)
Pathologic size (mm)
     Mean size (range) 18.5 (2-65)
     Median (interquartile range) 13.5 (7-27.3)
Extrathyroidal extension 
     No 19 (33.9)
     Perithyroidal 33 (58.9)
     Strap muscle 1 (1.8)
     Massive 3 (5.4)
Central lymph node metastasis  35 (62.5)
Lateral lymph node metastasis  22 (39.3)
Radioactive iodine ablation
     Yes 31 (55.4)
     No 25 (44.6)
Recurrence
     Contralateral thyroid 5 (8.9)
     Operation bed 6 (10.7)
     Neck lymph node metastasis 24 (42.9)
     Distant metastasis 1 (1.8)
     Multiple site metastasis 8 (14.3)
     Biochemical recurrence 12 (21.4)Papillary thyroid carcinoma with cystic changes
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CI, 1.066 to 4.596; P=0.033).
In group 2, thyroid cancers with a >25% cystic component were 
also significantly larger than those with a ≤25% cystic component 
in the case of the mean pathologic size (P<0.001). Lateral neck 
lymph node metastases were more frequently observed in thyroid 
cancers with a >25% cystic component (P=0.039). The follow-up 
period ranged from 12 to 115 months (mean, 85.7±28.6 months) 
for the 23 PTC patients with a >25% cystic component and from 
5 to 119 months (mean, 85.6±27.3 months) for the 530 patients 
with a ≤25% cystic component. Three recurrences occurred during 
the follow-up period in PTC patients with a >25% cystic component 
(13%), whereas 53 recurrences occurred in those with a ≤25% 
cystic component (10%; P=0.720). The cystic component of a tumor 
was not an independent predictor of recurrence (HR, 0.569; 95% 
CI, 0.164 to 1.976; P=0.375), using the multiple Cox proportional 
hazards model (Table 4). Independent predictors of recurrence were 
pathologic size (HR, 1.040; 95% CI, 1.012 to 1.070; P=0.005), male 
gender (HR, 2.232; 95% CI, 1.123 to 4.434; P=0.022), and lymph 
node metastasis (HR, 2.193; 95% CI, 1.055 to 4.558; P=0.035).
Discussion
PTC is the most common endocrine tumor arising from follicular cells 
of the thyroid, and its incidence has increased during recent years 
[10,11]. Most PTCs have an excellent prognosis, and factors known 
to be related to poor prognosis are age over 45 years, male gender, 
larger tumor size, presence of extrathyroidal invasion, or distant 
metastases at the time of diagnosis [12-19]. Mixed thyroid nodules, 
in which the tumor contains partially solid and cystic components, 
account for about 15.0%-53.8% of all thyroid nodules detected 
on US, and 17.6% of all cystic thyroid nodules are confirmed as 
malignant after thyroidectomy [8,20-23]. A predominant cystic 
change of thyroid cancer can be mistaken for a benign cystic 
hyperplastic nodule [1,8,22,24]. To distinguish benign nodules 
from malignancy in partially cystic thyroid nodules, US features 
such as eccentric configuration and presence of microcalcifications 
within the solid portion can be of help in an accurate diagnosis 
of thyroid malignancy [22,25-27]. Although US features and 
cytopathologic characteristics of cystic PTC have been established 
[3,4,9,25,26], studies on PTC showing a cystic change on US focus 
on its behaviors, in comparison to solid-appearing thyroid cancers 
on US, and its prognosis has not yet been demonstrated. In this 
study, we investigated the nature of PTC with a cystic change on 
US. Measuring the component of cystic change of PTC on US is 
subjective, and calculation of the precise cystic portion on US is not 
always possible. Therefore, we divided the masses into two groups 
according to the cystic components by using two different reference 
points of 25% and 50%, respectively. 
In this study, only 1.3% of the patients diagnosed with PTC 
had masses containing more than a 50% cystic component, and 
4.2% had masses containing more than a 25% cystic component. 
Previously reported prevalence of cystic changes was 2.5% and 6% 
in patients with PTC [1,2], and these percentages were higher than 
the values obtained in our study. To understand this difference, the 
process leading to a cystic change can be considered. The cystic 
change of a thyroid nodule may result from infarction or other 
destructive processes such as hemorrhage within the pre-existing 
follicles or cavities [28]. Nodule size may be affected by the grossly 
detectable cystic change, due to the presence of these follicles or 
cavities within the mass. The small percentage of PTC with cystic 
components in our study may be explained by the smaller size of 
PTC in our study than in other studies, since tumors of a smaller size 
are less likely to have areas of infarction or hemorrhagic cavities. 
Further, our study included nodules diagnosed as conventional PTC 
only, not other pathologies such as follicular thyroid carcinoma, 
medullary thyroid carcinoma, and undifferentiated thyroid 
carcinoma. This may have resulted in the lower percentage of thyroid 
cancer showing a cystic appearance in our study.
Table 4. Multivariate Cox proportional hazards regression analyses of variables predicting recurrence according to the cystic 
component
Variable HR (95% CI) P-value HR (95% CI) P-value
>50% cystic component 1.118 (0.255-4.910) 0.883 - -
>25% cystic component - - 0.569 (0.164-1.976) 0.375
Age 0.998 (0.975-1.022) 0.857 0.998 (0.975-1.022) 0.884
Pathologic size 1.035 (1.008-1.064) 0.012 1.040 (1.012-1.070) 0.005
Male gender 2.185 (1.093-4.369) 0.027 2.232 (1.123-4.434) 0.022
Extrathyroidal extension 1.539 (0.945-2.506) 0.083 1.535 (0.954-2.469) 0.077
Lymph node metastasis 2.213 (1.066-4.596) 0.033 2.193 (1.055-4.558) 0.035
HR, hazard ratio; CI, confidence interval.Ja Young Kim, et al.
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